Komori
OncoTherapy Science (4564) · RiskRestated

Risks related to patent issuance, scope of rights and disputes with third parties

First written in FY2016. 4 of 5 entries say "Restated". Latest entry: FY2025.

5entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20252016: 120162017: 120172018: 120182019: 020192020: 020202021: 020212022: 120222023: 020232024: 020242025: 12025
Same theme, other companies
Acquisition and validity of the company's intellectual property rights, and risk of infringement lawsuits by third partiesA theme 67 companies write about · 67 as a headwind · 0 as a tailwind

38 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 67 companies compared. The sentences above are computed from all 67.
Full recordFilings, disclosures and news, newest first
  1. FY2025RestatedAnnual report

    「However, there is no guarantee that all of the patents in question will be granted, nor that our rights can be reliably protected through patent applications.」

    The company continues to disclose risks related to the granting of patents, the scope of rights, third-party use of the technology, and disputes.
  2. FY2023-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    The company states that there have been no material changes in the risks related to the granting of patents, the scope of rights, third-party use of the technology, and disputes.
  3. FY2018RestatedAnnual report

    「However, there is no guarantee that all of the patents in question will be granted, nor that our rights can be reliably protected through patent applications.」

    The company continues to disclose risks related to the granting of patents, the scope of rights, third-party use of the technology, and disputes.
  4. FY2017RestatedAnnual report

    「There is no guarantee that all of the patents in question will be granted, nor that our rights can be reliably protected through patent applications.」

    The company continues to disclose potential risks related to the granting of patents, the scope of rights, third-party use of the technology, and disputes.
  5. FY2016First statedAnnual report

    「There is no guarantee that all of the patents in question will be granted, nor that our rights can be reliably protected through patent applications.」

    The company discloses risks related to the legal interpretation of gene-related patents, third-party use of the technology, and the costs and business impact of future litigation or claims.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for OncoTherapy Science yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risks related to patent issuance, scope of rights and disputes with third parties | OncoTherapy Science,Inc. (4564) | Komori